TB-500 side effects and the tumor/angiogenesis safety signal in the research literature

Why TB-500 side effects can't be stated as a human profile

A clear-eyed account of TB-500 side effects has to begin with an absence: no completed controlled human trials of the TB-500 heptapeptide exist for any indication, so a human side-effect profile for the fragment is not established ^[5]. The closest human safety data are for intravenous full-length thymosin beta-4, which was well tolerated to 1260 mg across 14 days in a Phase 1 study of 40 healthy volunteers, with no dose-limiting toxicities or serious adverse events ^[6]. That tolerability belongs to the parent protein given intravenously — it is reassuring as far as it goes, and it does not transfer automatically to a different molecule given by a different route.

So the side-effect question for TB-500 is not "what is the rate of nausea" — there is no controlled dataset to answer that. It is a question about a mechanistic signal that runs through the same biology that makes thymosin beta-4 a repair peptide. That signal is the subject of this page.

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in several cancers and is implicated in metastasis and tumor angiogenesis ^[7]; the same pro-migratory, pro-angiogenic properties that aid tissue repair could theoretically support tumor progression ^[7]. In human pancreatic cancer cells, thymosin beta-4 was overexpressed and stimulated proliferation- and invasion-related behavior, reinforcing the oncologic concern ^[8]. This is a theoretical safety signal derived from preclinical and tumor-cell data — not a demonstrated outcome of the TB-500 7-mer in humans ^[5][7]. It is, however, the single most important caution on this site, and it is the reason a repair-promoting peptide deserves caution rather than enthusiasm.

Does TB-500 promote angiogenesis and is that a safety concern?

Thymosin beta-4 induces VEGF in a HIF-1α-dependent manner and drives endothelial migration, producing the new-vessel formation that aids repair ^[10]. Because tumors also exploit angiogenesis to grow and spread, that same pro-angiogenic activity is part of the theoretical oncologic safety signal ^[7][10]. The mechanism that makes the molecule interesting for wounds is, in a different context, the mechanism that makes it a concern — which is exactly why this site keeps the "confirmed repair" findings and the "safety caution" findings in separate columns.

Is TB-500 safe according to the research?

There is no body of research that establishes the TB-500 fragment as safe in humans, because the controlled human trials that would answer the question have not been done ^[5]. The available human safety data are for intravenous full-length thymosin beta-4 (well tolerated to 1260 mg in a Phase 1 study) ^[6]; the principal unresolved concern is the tumor and angiogenesis signal carried by thymosin beta-4 ^[7][8]. "Unstudied in humans" and "safe" are not the same statement, and only the first is supported.

What are the side effects of TB-500?

No completed controlled human trials of the TB-500 heptapeptide exist, so a human side-effect profile is not established ^[5]. The closest human safety data are for intravenous full-length thymosin beta-4, well tolerated to 1260 mg in a Phase 1 study with no dose-limiting toxicities ^[6]; the principal theoretical concern is the tumor and angiogenesis signal ^[7]. Research-grade material purity and correct sequence are an added, separate concern ^[5].

Is TB-500 safe for long-term use?

Long-term safety of the TB-500 fragment is unstudied in humans ^[5]. The longest controlled human exposure to the parent protein is 14 days of intravenous thymosin beta-4 ^[6]; chronic dosing data come only from animals — for example 150 µg intraperitoneally twice weekly for 6 months in mdx mice ^[9] — and the tumor-angiogenesis concern is most relevant precisely to prolonged exposure ^[7].

What are the negative effects of TB-500?

Beyond the unproven human safety profile, preclinical results temper the narrative directly. In mdx mice, chronic thymosin beta-4 raised regenerating-fiber counts but did not improve strength, cardiac function, or fibrosis ^[9]; and systemic thymosin beta-4 failed to limit myocardial ischemia-reperfusion injury in pigs ^[14]. Research-grade material purity — including whether a vial contains the fragment or the full-length protein — is an added concern that complicates interpreting any anecdotal result ^[5].

The material-quality caveat

One side-effect risk has nothing to do with the molecule's biology and everything to do with supply. Research-grade TB-500 is sold for laboratory use, outside the manufacturing oversight that applies to approved drugs, and peptide identity, purity, and correct sequence — full-length versus fragment — are not guaranteed in unregulated supply ^[5]. That uncertainty both adds risk and makes anecdotal reports hard to interpret, because the substance in any given vial may not be what the label claims ^[5]. Any reading of TB-500 side effects has to hold that variable open. The regulatory framing — FDA non-approval, the 503A category, and how lawful compounded access works — is on the TB-500 legal status and FDA 503A category page.